Horwitz Lawrence D, Horwitz Marcus A
1 Division of Cardiology, Department of Medicine, University of Colorado Health Sciences Center , Denver, Colorado.
Antioxid Redox Signal. 2014 Dec 1;21(16):2246-61. doi: 10.1089/ars.2013.5789. Epub 2014 Jun 20.
Exochelins are lipid- and water-soluble siderophores of Mycobacterium tuberculosis with unique properties that endow them with exceptional pharmacologic utility. Exochelins can be utilized as probes to decipher the role of iron in normal and pathological states, and, since they rapidly cross cell membranes and chelate intracellular iron with little or no toxicity, exochelins are potentially useful for the treatment of a number of iron-dependent pathological phenomena.
In animal models, exochelins have been demonstrated to have promise for the treatment of transfusion-related iron overload, restenosis after coronary artery angioplasty, cancer, and oxidative injury associated with acute myocardial infarction and transplantation.
To be clinically effective, iron chelators should be able to rapidly enter cells and chelate iron at key intracellular sites. Desferri-exochelins, and other lipid-soluble chelators, can readily cross cell membranes and remove intracellular free iron; whereas deferoxamine, which is lipid insoluble, cannot do so. Clinical utility also requires that the chelators be nontoxic, which, we hypothesize, includes the capability to prevent iron from catalyzing free radical reactions which produce •OH or other reactive oxygen species. Lipid-soluble iron chelators currently available for clinical application are bidentate (deferiprone) or tridentate (desferasirox) molecules that do not block all six sites on the iron molecule capable of catalyzing free radical reactions. In contrast, desferri-exochelins are hexadentate molecules, and by forming a one-to-one binding relationship with iron, they prevent free radical reactions.
Clinical studies are needed to assess the utility of desferri-exochelins in the treatment of iron-dependent pathological disorders.
外排螯合素是结核分枝杆菌的脂溶性和水溶性铁载体,具有独特的性质,赋予它们特殊的药理效用。外排螯合素可用作探针来解读铁在正常和病理状态下的作用,而且,由于它们能迅速穿过细胞膜并螯合细胞内铁,几乎没有或没有毒性,外排螯合素在治疗多种铁依赖性病理现象方面具有潜在用途。
在动物模型中,外排螯合素已被证明在治疗输血相关铁过载、冠状动脉血管成形术后再狭窄、癌症以及与急性心肌梗死和移植相关的氧化损伤方面具有前景。
为了在临床上有效,铁螯合剂应能够迅速进入细胞并在关键的细胞内位点螯合铁。去铁外排螯合素和其他脂溶性螯合剂能够轻易穿过细胞膜并去除细胞内游离铁;而脂不溶性的去铁胺则不能。临床效用还要求螯合剂无毒,我们推测这包括防止铁催化产生•OH或其他活性氧物质的自由基反应的能力。目前可用于临床的脂溶性铁螯合剂是双齿(去铁酮)或三齿(地拉罗司)分子,它们不能阻断铁分子上所有六个能够催化自由基反应的位点。相比之下,去铁外排螯合素是六齿分子,通过与铁形成一对一的结合关系,它们可防止自由基反应。
需要进行临床研究以评估去铁外排螯合素在治疗铁依赖性病理疾病中的效用。